What Is The Current and Historic Market Size Analysis Of The Dendritic Cell Cancer Vaccine Market?
The dendritic cell cancer vaccine market has seen considerable growth due to a variety of factors.
• The dendritic cell cancer vaccine market has expanded rapidly in recent years. It will grow from $2.46 billion in 2024 to $2.71 billion in 2025, at a CAGR of 10.5%.
This growth is driven by cancer awareness initiatives, investment in manufacturing capabilities, exploration of combination therapies, adoption of precision medicine, and better understanding of the immune system.
What Is The Forecast For The Dendritic Cell Cancer Vaccine Market Size?
The dendritic cell cancer vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• The dendritic cell cancer vaccine market is expected to grow to $4 billion by 2029, expanding at a CAGR of 10.1%.
Growth is driven by omics technologies integration, the aging population, digital health solutions, patient advocacy, and AI integration. Trends include advances in regenerative medicine, vaccine delivery innovations, patient-centric development, neoantigen identification, and next-generation vaccine platforms.
What Are The Essential Drivers Behind The Growth Of The Dendritic Cell Cancer Vaccine Market?
The growing number of cancer cases is expected to propel the growth of the dendritic cell cancer vaccine market. Cancer is caused by the uncontrolled growth of abnormal cells and is influenced by lifestyle, environmental, and genetic factors. Dendritic cell cancer vaccines aim to boost the body’s immune response to target and fight cancer cells. For instance, a February 2024 report by the World Health Organization projected 35 million new cancer cases by 2050, representing a 77% increase from 2022. Therefore, the rising cancer incidence is contributing to the growth of the dendritic cell cancer vaccine market.
How Is The Global Dendritic Cell Cancer Vaccine Market Divided Into Key Segments?
The dendritic cell cancer vaccine market covered in this report is segmented –
1) By Product: CreaVax, Sipuleucel-T (Provenge), Other Products
2) By Distribution Channel: Hospitals, Cancer Centers, Ambulatory Surgical Centers, Clinics
3) By Application: Pediatrics, Adults
4) By End User: Oncology, Research Institutions, Biopharmaceutical Companies
Subsegments:
1) By Creavax: Creavax In Clinical Trials, Creavax Commercialization
2) By Sipuleucel-T (Provenge): Sipuleucel-T In Prostate Cancer, Sipuleucel-T Market Share, Sipuleucel-T Regulatory Approvals
3) By Other Products: Dcvax, Oncovax, GVAX, Other Experimental Dendritic Cell Vaccines
Pre-Book The Dendritic Cell Cancer Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Dendritic Cell Cancer Vaccine Market?
Companies in the dendritic cell cancer vaccine market are forming strategic collaborations to develop curative cancer vaccines. These partnerships aim to improve clinical care. For example, in May 2023, the Walter and Eliza Hall Institute collaborated with Peter MacCallum Cancer Centre to develop a cancer vaccine with MRFF funding. This initiative focuses on dendritic cell-based vaccinations to help cancer patients fight the disease.
Who Are the Key Players In The Dendritic Cell Cancer Vaccine Market?
Major companies operating in the dendritic cell cancer vaccine market are:
• Dendreon Pharmaceuticals LLC
• Celgene Corporation
• Cognate BioServices Inc.
• APAC Biotech
• Asterias Biotherapeutics Inc
• Batavia Biosciences
• Medigene AG
• Zelluna Immunotherapy AS
• Diakonos Oncology
• Elios Therapeutics LLC
• Northwest Biotherapeutics
• Oncopep Inc.
• PDC*line Pharma SA
• SillaJen Biotherapeutics Inc.
• VLP Therapeutics
• ImmunityBio Inc.
• Celldex Therapeutics Inc.
• Bellicum Pharmaceuticals
• Argos Therapeutics Inc.
• DCPrime
• NuGenerex Immuno-Oncology
What Are The Regional Insights Into The Dendritic Cell Cancer Vaccine Market?
North America was the largest region in the dendritic cell cancer vaccine market in 2023. The regions covered in the dendritic cell cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
